Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial
Abstract
Introduction: COVID-19 is associated with a cascade of inflammatory responses potentially lead to devastating outcomes. Objectives: The current study aims to investigate the efficacy of montelukast, a leukotriene receptor antagonist (LTRA), on laboratory parameters in COVID-19 infection. Patients and Methods: The current randomized clinical trial (RCT) conducted on 67 patients with moderate-to-severe COVID-19 pneumonia in 2020-2021. All patients received treatments according to the national guidelines, while the case group additionally applied 10 mg montelukast for 14 days. The clinical disease improvement and laboratory data (complete blood cells count and differentiation, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), D-dimer, blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) were assessed within two weeks after the infection and compared between the groups. Results: Baseline assessed parameters did not differ between the groups (P>0.05). A significant decrease in pulse rate, also in normal ranges, was notified in the montelukast-treated group compared with the baseline (P=0.001) and with controls (P=0.033); however, other vital signs were not statistically different (P>0.05). CRP (P<0.001), ESR (P=0.008), BUN (P=0.015), and AST (P<0.001) significantly decreased in the post-intervention assessment of the montelukast-treated group. The comparison of the groups in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 67 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.